# PDUFA dates October 2025: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2025-10

> 184 FDA catalysts are dated in October 2025, including 9 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in October 2025?

PDUFA dates in October 2025: Tecentriq® (atezolizumab, JAZZ) on October 7, 2025; Cingulate Inc. (CING) on October 9, 2025; tividenofusp alfa (DNLI) on October 13, 2025; ZORYVE (roflumilast, ARQT) on October 13, 2025; AMGEN INC (AMGN) on October 19, 2025; GSK plc (GSK) on October 23, 2025; and 3 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2025-10)

Source: Press release filed with the SEC (EX-99), accession 0001232524-25-000061, https://www.sec.gov/Archives/edgar/data/1232524/000123252425000061/a2q25financialpr.htm (retrieved 2026-11-12). Last confirmed 2025-08-06. Cite: https://sec-api.dev/fda-calendar/2025-10#answer

## PDUFA dates in October 2025

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| October 7, 2025 | Jazz Pharmaceuticals plc | JAZZ | Tecentriq® (atezolizumab) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000061/a2q25financialpr.htm) |
| October 9, 2025 | Cingulate Inc. | CING |  |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315226010882/form10-k.htm) |
| October 13, 2025 | Denali Therapeutics Inc. | DNLI | tividenofusp alfa | mucopolysaccharidosis type II | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000180/dnli-20251013.htm) |
| October 13, 2025 | Arcutis Biotherapeutics, Inc. | ARQT | ZORYVE (roflumilast) | atopic dermatitis in children ages 2 to 5 with an | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000122/pressreleaseex991q22025.htm) |
| October 19, 2025 | AMGEN INC | AMGN |  | chronic rhinosinusitis with nasal polyps | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/amgn-20250630earningsrelea.htm) |
| October 23, 2025 | GSK plc | GSK |  |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425008641/a0713t-gskplc2ndquarterre.htm) |
| October 25, 2025 | Syndax Pharmaceuticals Inc | SNDX | Revuforj® (revumenib) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_2.htm) |
| October 25, 2025 | Merck & Co., Inc. | MRK | WINREVAIR (sotatercept) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465925071380/tm2521736d1_ex99-1.htm) |
| October 25, 2025 | Syndax Pharmaceuticals Inc | SNDX | NIKTIMVO (axatilimab) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_1.htm) |

## All catalysts in October 2025

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 1, 2025 | [ZYCUBO (CUTX-101) complete response letter (CRL)](https://sec-api.dev/pdufa/cutx-101) | FBIO | Menkes disease in pediatric patients | completed, complete response letter | "On October 1, 2025, Fortress Biotech, Inc. issued a press release announcing that the U.S. Food and Drug Administration issued a complete response letter for CUTX-101 (copper histidinate)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1429260/000110465925095366/fbio-20251001x8k.htm)) |
| October 1, 2025 | [Joenja® (leniolisib) NDA/BLA acceptance](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed | "On October 1, 2025, we announced that the FDA had accepted the sNDA and granted Priority Review of the application and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000049/a2025q3pressrelease.htm)) |
| October 1, 2025 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Overweight or Obesity; CKD; Type 2 Diabetes | completed | "NCT05936151 (A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-11-09." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05936151)) |
| October 1, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06015308 (A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06015308)) |
| October 1, 2025 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY | Myelodysplastic Syndromes | completed | "NCT06045689 (A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06045689)) |
| October 1, 2025 | [GSK3915393 primary completion](https://sec-api.dev/pdufa/gsk3915393) | GSK | Idiopathic Pulmonary Fibrosis | withdrawn | "NCT06317285 (A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-09-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06317285)) |
| October 1, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes | completed | "NCT06323174 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06323174)) |
| October 1, 2025 | [Anti-(integrin beta-3) human monoclonal antibody primary completion](https://sec-api.dev/pdufa/anti-integrin-beta-3-human-monoclonal-antibody) | RLYB | Fetal and Neonatal Alloimmune Thrombocytopenia | withdrawn | "NCT06435845 (Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Rallybio; Results First Posted 2026-03-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06435845)) |
| October 1, 2025 | [Nnc0487-0111 subcutanous primary completion](https://sec-api.dev/pdufa/nnc0487-0111-subcutanous) | NVO | Type 2 Diabetes (T2D) | completed | "NCT06542874 (A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06542874)) |
| October 2, 2025 | [SZ-001 topline data readout](https://sec-api.dev/pdufa/sz-001) | AVXL |  | completed, positive | "On October 2, 2025, Anavex announced positive topline results from its placebo-controlled Phase 2 clinical study evaluating ANAVEX®3-71 for the treatment of schizophrenia in adults on stable antipsychotic medication (ANAVEX3-71-SZ-001, NCT06245213)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1314052/000173112225001591/e7068_ex99-1.htm)) |
| October 2, 2025 | [OV329 topline data readout](https://sec-api.dev/pdufa/ov329) | OVID |  | completed, positive | "Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced positive topline results from its Phase 1 healthy volunteer study evaluating the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) activity of OV329, a next generation GABA-aminotransferase (GABA-AT) inhibitor being developed for drug-resistant epilepsies." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/d45212dex991.htm)) |
| October 2, 2025 | [Scemblix (asciminib) label expansion decision](https://sec-api.dev/pdufa/asciminib) | NVS |  | completed, approved | "NDA215358 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20251002, review_priority STANDARD; sponsor_name NOVARTIS; product SCEMBLIX (ASCIMINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215358%22)) |
| October 2, 2025 | [Zepzelca (lurbinectedin) label expansion decision](https://sec-api.dev/pdufa/lurbinectedin) | JAZZ |  | completed, approved | "NDA213702 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20251002, review_priority PRIORITY; sponsor_name JAZZ; product ZEPZELCA (LURBINECTEDIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213702%22)) |
| October 2, 2025 | [Cerezyme (imiglucerase) primary completion](https://sec-api.dev/pdufa/imiglucerase) | SNY | Gaucher's Disease Type III | completed | "NCT05222906 (Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-02 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05222906)) |
| October 2, 2025 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Biliary Tract Cancer | completed | "NCT05771480 (Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-02 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05771480)) |
| October 3, 2025 | [Fordadistrogene movaparvovec primary completion](https://sec-api.dev/pdufa/fordadistrogene-movaparvovec) | PFE | Muscular Dystrophy, Duchenne | withdrawn | "NCT05429372 (Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-03 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05429372)) |
| October 4, 2025 | [ZORYVE (roflumilast) label expansion decision](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | completed, approved | "NDA215985 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20251004, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22)) |
| October 6, 2025 | [Cariprazine flexible dose primary completion](https://sec-api.dev/pdufa/cariprazine-flexible-dose) | ABBV | Schizophrenia; Bipolar I Disorder; Autism Spectrum Disorder (ASD) | completed | "NCT04578756 (Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-06 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04578756)) |
| October 6, 2025 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Advanced or Metastatic Non-Small Cell Lung Cancer | completed | "NCT05450692 (A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-06 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05450692)) |
| October 6, 2025 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Type 2 Diabetes Mellitus (T2DM) | completed | "NCT06660173 (A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-10-06 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06660173)) |
| October 6, 2025 | [NEREUSTM (tradipitant) primary completion](https://sec-api.dev/pdufa/tradipitant) | VNDA | Obesity | completed | "NCT06804603 (A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-06 (ACTUAL); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06804603)) |
| October 7, 2025 | [ADI-001 interim data readout](https://sec-api.dev/pdufa/adi-001) | ACET |  | completed, positive | "On October 7, 2025, we announced positive initial safety and efficacy data from the seven patients (five LN and two SLE patients) dosed with ADI-001 in the ongoing Phase 1 trial, with follow-up ranging from two to nine months, as of an August 31, 2025 data cut-off date." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1720580/000119312525266880/acet-20250930.htm)) |
| October 7, 2025 | [Tecentriq® (atezolizumab) PDUFA date](https://sec-api.dev/pdufa/atezolizumab) | JAZZ |  | scheduled | "•Zepzelca and atezolizumab (Tecentriq®) combination granted U.S. FDA Priority Review for 1L maintenance treatment of ES-SCLC based on positive data from IMforte trial; PDUFA action date of October 7, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000061/a2q25financialpr.htm)) |
| October 7, 2025 | [Opsumit (macitentan) primary completion](https://sec-api.dev/pdufa/macitentan) | JNJ | Pulmonary Arterial Hypertension | completed | "NCT04273945 (Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-07 (ACTUAL); Lead Sponsor Actelion." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04273945)) |
| October 7, 2025 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Chronic Kidney Disease; CKD; Cardiac Disease | withdrawn | "NCT05746559 (ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-10-07 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2026-10-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05746559)) |
| October 7, 2025 | [Tapinarof cream, 1% primary completion](https://sec-api.dev/pdufa/tapinarof-cream-1) | TEVA | Plaque Type Psorisis | completed | "NCT06742957 (Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-07 (ACTUAL); Lead Sponsor Teva Pharmaceuticals USA." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06742957)) |
| October 7, 2025 | [Bxcl501 sublingual film primary completion](https://sec-api.dev/pdufa/bxcl501-sublingual-film) | BTAIQ | Bipolar I Disorder; Bipolar II Disorder; Schizophrenia | completed | "NCT07116694 (Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-07 (ACTUAL); Lead Sponsor BioXcel Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07116694)) |
| October 8, 2025 | [Libtayo (cemiplimab-rwlc) label expansion decision](https://sec-api.dev/pdufa/cemiplimab-rwlc) | REGN |  | completed, approved | "BLA761097 SUPPL-30 (Efficacy): submission_status AP, submission_status_date 20251008, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22)) |
| October 8, 2025 | [Cadefrecitinib primary completion](https://sec-api.dev/pdufa/cadefrecitinib) | LKFT | Systemic Lupus Erythematosus | completed | "NCT05856448 (A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-08 (ACTUAL); Lead Sponsor Lakefront Biotherapeutics NV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05856448)) |
| October 9, 2025 | [Cingulate Inc. PDUFA date](https://sec-api.dev/companies/cing/catalysts) | CING |  | scheduled | "On October 9, 2025, the NDA submission was accepted by the FDA and a PDUFA target action date of" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315226010882/form10-k.htm)) |
| October 9, 2025 | [Praluent (alirocumab) label expansion decision](https://sec-api.dev/pdufa/alirocumab) | REGN |  | completed, approved | "BLA125559 SUPPL-47 (Efficacy): submission_status AP, submission_status_date 20251009, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product PRALUENT (ALIROCUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125559%22)) |
| October 9, 2025 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959525000112/nrix-20251009xexx991.htm)) |
| October 9, 2025 | [Venclexta (venetoclax) primary completion](https://sec-api.dev/pdufa/venetoclax) | ABBV | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) | completed | "NCT05105841 (Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-09 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05105841)) |
| October 9, 2025 | [Sar444656 (kt-474) primary completion](https://sec-api.dev/pdufa/sar444656-kt-474) | SNY | Hidradenitis Suppurativa | withdrawn | "NCT06028230 (A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-09 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06028230)) |
| October 10, 2025 | [Saphnelo (anifrolumab-fnia) complete response letter (CRL)](https://sec-api.dev/pdufa/anifrolumab-fnia) | AZN |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761451_20251010.pdf%22)) |
| October 10, 2025 | [UZEDY (risperidone) FDA approval](https://sec-api.dev/pdufa/risperidone) | TEVA |  | completed, approved | "On October 10, 2025, it was announced that the FDA approved UZEDY as a once-monthly extended-release injectable suspension as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar 1 disorder (BD-1) in adults." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm)) |
| October 10, 2025 | [Praxis Precision Medicines, Inc. primary completion](https://sec-api.dev/companies/prax/catalysts) | PRAX | Essential Tremor | completed | "NCT06087276 (Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2025-10-10 (ACTUAL); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06087276)) |
| October 10, 2025 | [Iclusig (ponatinib hydrochloride) label expansion decision](https://sec-api.dev/pdufa/ponatinib) | TAK |  | completed, approved | "NDA203469 SUPPL-38 (Efficacy): submission_status AP, submission_status_date 20251010, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product ICLUSIG (PONATINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203469%22)) |
| October 10, 2025 | [UZEDY (risperidone) label expansion decision](https://sec-api.dev/pdufa/risperidone) | TEVA |  | completed, approved | "NDA213586 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20251010, review_priority STANDARD; sponsor_name TEVA; product UZEDY (RISPERIDONE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213586%22)) |
| October 10, 2025 | [RINVOQ® (upadacitinib) label expansion decision](https://sec-api.dev/pdufa/upadacitinib) | ABBV |  | completed, approved | "NDA211675 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20251010, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22)) |
| October 13, 2025 | [Tividenofusp alfa PDUFA date](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | mucopolysaccharidosis type II | scheduled | "On October 13, 2025, Denali Therapeutics Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for the Company's Biologics License Application (BLA) seeking accelerated approval of tividenofusp alfa for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000180/dnli-20251013.htm)) |
| October 13, 2025 | [ZORYVE (roflumilast) PDUFA date](https://sec-api.dev/pdufa/roflumilast) | ARQT | atopic dermatitis in children ages 2 to 5 with an | completed, approved | "•The Company has been assigned a Prescription Drug User Fee Act (PDUFA) action date of October 13, 2025 for the supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% for the treatment of atopic dermatitis in children ages 2 to 5 years old." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000122/pressreleaseex991q22025.htm)) |
| October 13, 2025 | [Nai + pembrolizumab primary completion](https://sec-api.dev/pdufa/nai-pembrolizumab) | IBRX | Non Small Cell Lung Cancer | withdrawn | "NCT03520686 (Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03520686)) |
| October 13, 2025 | [N-803 primary completion](https://sec-api.dev/pdufa/n-803) | IBRX | Pancreatic Cancer | completed | "NCT04390399 (Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04390399)) |
| October 13, 2025 | [TEVIMBRA® (tislelizumab) primary completion](https://sec-api.dev/pdufa/tislelizumab) | ONC | Classical Hodgkin Lymphoma | withdrawn | "NCT04486391 (Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04486391)) |
| October 13, 2025 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-cell Lymphoma | completed | "NCT04628494 (A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04628494)) |
| October 13, 2025 | [TECVAYLI (teclistamab) primary completion](https://sec-api.dev/pdufa/teclistamab) | JNJ | Multiple Myeloma | completed | "NCT05572515 (A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05572515)) |
| October 13, 2025 | [Cadefrecitinib primary completion](https://sec-api.dev/pdufa/cadefrecitinib) | LKFT | Dermatomyositis | completed | "NCT05695950 (A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Lakefront Biotherapeutics NV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05695950)) |
| October 13, 2025 | [Dor/isl primary completion](https://sec-api.dev/pdufa/dor-isl) | MRK | HIV-1 Infection | completed | "NCT05705349 (DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05705349)) |
| October 13, 2025 | [Mrna-1083 composition 1 dose a lot a primary completion](https://sec-api.dev/pdufa/mrna-1083-composition-1-dose-a-lot-a) | MRNA | Influenza; SARS-CoV-2 | completed | "NCT06864143 (A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06864143)) |
| October 13, 2025 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | completed | "NCT07226752 (A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226752)) |
| October 14, 2025 | [JOHNSON & JOHNSON earnings report](https://sec-api.dev/companies/jnj/catalysts) | JNJ |  | completed | "In a separate press release issued today, Johnson & Johnson announced its third-quarter results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/200406/000020040625000201/a2025q3exhibit993.htm)) |
| October 14, 2025 | [Cingulate Inc. NDA/BLA acceptance](https://sec-api.dev/companies/cing/catalysts) | CING | ADHD for children and adults | completed | "October 14, 2025, the Company announced that the FDA has accepted for review the NDA for CTx-1301 (dexmethylphenidate), the Company's lead candidate for the treatment of ADHD for children and adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315225017931/form8-k.htm)) |
| October 14, 2025 | [Linoserpaturev interim data readout](https://sec-api.dev/pdufa/linoserpaturev) | CADL |  | completed, positive | "On October 14, 2025, the Company announced positive interim data from its ongoing phase 1b clinical trial of CAN-3110 in recurrent glioblastoma." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1841387/000119312525238254/cadl-20251014.htm)) |
| October 14, 2025 | [KRESLADI (marnetegragene autotemcel) NDA/BLA acceptance](https://sec-api.dev/pdufa/marnetegragene-autotemcel) | RCKT |  | completed | "On October 14, 2025, Rocket Pharmaceuticals, Inc. (the "Company") announced that the U.S. Food and Drug Administration (the "FDA") has accepted resubmission of the Biologics License Application (BLA) for KRESLADI™ (marnetegragene autotemcel; marne-cel), a lentiviral vector (LV)-based investigational gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I), a rare genetic immune disorder that predisposes patients to recurrent and fatal infections and is near-uniformly fatal in childhood without an allogeneic hematopoietic stem cell transplant." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1281895/000114036125038030/ef20057000_8k.htm)) |
| October 14, 2025 | [PTR (ptr) NDA/BLA acceptance](https://sec-api.dev/pdufa/ptr) | CING | Attention-Deficit/Hyperactivity Disorder | completed | "CITY, Kan., October 14, 2025 — Cingulate Inc. (NASDAQ: CING) a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CTx-1301 (dexmethylphenidate), the company's lead candidate for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adults." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315225017931/ex99-1.htm)) |
| October 14, 2025 | [Release (release) NDA/BLA acceptance](https://sec-api.dev/pdufa/release) | CING | attention deficit/hyperactivity | completed | "October 14, 2025, Cingulate Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted for review the New Drug Application ("NDA") for CTx-1301 (dexmethylphenidate), the Company's lead candidate for the treatment of attention deficit/hyperactivity ("ADHD") for children and adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315225017931/form8-k.htm)) |
| October 14, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Triple Negative Breast Neoplasms | completed | "NCT03036488 (Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-14 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03036488)) |
| October 14, 2025 | [MAS825 primary completion](https://sec-api.dev/pdufa/mas825) | NVS |  | completed | "NCT04641442 (Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-10-14 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04641442)) |
| October 14, 2025 | [Bemarituzumab primary completion](https://sec-api.dev/pdufa/bemarituzumab) | AMGN | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | withdrawn | "NCT05111626 (Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-10-14 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05111626)) |
| October 14, 2025 | [Colgate cavity protection toothpaste primary completion](https://sec-api.dev/pdufa/colgate-cavity-protection-toothpaste) | CL | Sensitivity, Tooth | completed | "NCT07149376 (To Assess the Efficacy of a Toothpaste Containing 8% Arginine as Compared to Colgate Cavity Protection Toothpaste in the Reduction of Dentinal Hypersensitivity.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-14 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07149376)) |
| October 15, 2025 | [ABBOTT LABORATORIES earnings report](https://sec-api.dev/companies/abt/catalysts) | ABT |  | completed | "Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1800/000162828025045049/abt-2025q3xexhibitx991.htm)) |
| October 15, 2025 | [Bla761495 FDA approval](https://sec-api.dev/pdufa/bla761495) | MRK |  | completed, approved | "BLA761495 ORIG-1 (Type 9 - New indication submitted as distinct BLA, consolidated): submission_status AP, submission_status_date 20251015, review_priority PRIORITY; sponsor_name MERCK SHARP AND DOHME LLC; product n/a." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761495%22)) |
| October 15, 2025 | [Tasigna (nilotinib hydrochloride) primary completion](https://sec-api.dev/pdufa/nilotinib) | NVS | Chronic Myeloid Leukemia | withdrawn | "NCT03874858 (A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-15 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03874858)) |
| October 2025 | [Vudalimab primary completion](https://sec-api.dev/pdufa/vudalimab) | XNCR | Ovarian Cancer; Clear Cell Carcinoma; Endometrial Cancer | delayed | "NCT05032040 (A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-10-15 (ESTIMATED); Lead Sponsor Xencor, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05032040)) |
| October 15, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | completed | "NCT05726227 (A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-15 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05726227)) |
| October 15, 2025 | [Londamocitinib primary completion](https://sec-api.dev/pdufa/londamocitinib) | AZN | Asthma | completed | "NCT06435273 (Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-15 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06435273)) |
| October 15, 2025 | [REGN5381 primary completion](https://sec-api.dev/pdufa/regn5381) | REGN | Uncontrolled Hypertension | withdrawn | "NCT06833190 (REGN5381 in Adult Participants With Uncontrolled Hypertension): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-15 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06833190)) |
| October 16, 2025 | [Pulmatrix, Inc. earnings report](https://sec-api.dev/companies/pulm/catalysts) | PULM |  | completed | "Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1574235/000149315225018252/ex99-1.htm)) |
| October 16, 2025 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed, positive | "On October 16, 2025, the Company announced positive topline results for the Phase 3 Essential3 program of ulixacaltamide in essential tremor ("ET")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000100/prax-20251016.htm)) |
| October 16, 2025 | [Ingrezza Sprinkle (valbenazine tosylate) primary completion](https://sec-api.dev/pdufa/valbenazine) | NBIX | Dyskinesia; Cerebral Palsy | completed | "NCT05206513 (Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-16 (ACTUAL); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05206513)) |
| October 16, 2025 | [Dor/isl primary completion](https://sec-api.dev/pdufa/dor-isl) | MRK | HIV Infection | completed | "NCT05766501 (A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-16 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05766501)) |
| October 16, 2025 | [ARGX-117 primary completion](https://sec-api.dev/pdufa/argx-117) | ARGX | Delayed Graft Function | completed | "NCT05907096 (ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-10-16 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05907096)) |
| October 16, 2025 | [Zilretta primary completion](https://sec-api.dev/pdufa/zilretta) | PCRX | Osteoarthritis of Hip | withdrawn | "NCT06977568 (A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-16 (ACTUAL); Lead Sponsor Pacira Pharmaceuticals, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06977568)) |
| October 16, 2025 | [Zimrixby (rituximab-cdxx) complete response letter (CRL)](https://sec-api.dev/pdufa/rituximab-cdxx) | RDY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761376_20251016.pdf%22)) |
| October 16, 2025 | [Xeljanz (tofacitinib citrate) label expansion decision](https://sec-api.dev/pdufa/tofacitinib) | PFE |  | completed, approved | "NDA203214 SUPPL-39 (Efficacy): submission_status AP, submission_status_date 20251016, review_priority STANDARD; sponsor_name PF PRISM CV; product XELJANZ (TOFACITINIB CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203214%22)) |
| October 17, 2025 | [Ivonescimab earnings report](https://sec-api.dev/pdufa/ivonescimab) | SMMT |  | completed | "1 Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025 Summit Plans to Submit a BLA in Q4 2025 for Ivonescimab based on HARMONi Global Phase III Study Results Expansion of Summit's Global Phase III Development Program Starts with Initiation of HARMONi-GI3, a New Study in 1L CRC: Summit to Initiate an Additional Set of Phase III Clinical Trials with Details to Come in Q1 2026 Ivonescimab with Chemotherapy Reduces the Risk of Disease Progression or Death by 48% Compared to Chemotherapy Alone in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy with Consistent Data across Regions Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40%, Median PFS of 11.14 Months, Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy, Median PFS 6.90 Months, in 1L Treatment of Patients with Squamous NSCLC in Phase III HARMONi-6 Study Conducted by Akeso in China HARMONi-3 Global Phase III Study Analyses Will Be Split by Histology: Squamous NSCLC Cohort Expected to Complete Enrollment First Half of 2026 with Data Readout Expected Second Half 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1599298/000159929825000156/a2025_prx1020xq32025earn.htm)) |
| October 17, 2025 | [Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) label expansion decision](https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc) | ARGX |  | completed, approved | "BLA761304 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20251017, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22)) |
| October 17, 2025 | [Vyvgart (efgartigimod alfa) label expansion decision](https://sec-api.dev/pdufa/efgartigimod-alfa) | ARGX |  | completed, approved | "BLA761195 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20251017, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART (EFGARTIGIMOD ALFA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761195%22)) |
| October 17, 2025 | [JNJ-63733657 primary completion](https://sec-api.dev/pdufa/jnj-63733657) | JNJ | Alzheimer Disease; Cognitive Dysfunction; Dementia | withdrawn | "NCT04619420 (A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-17 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-11-05." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04619420)) |
| October 17, 2025 | [TAK-279 primary completion](https://sec-api.dev/pdufa/tak-279) | TAK | Generalized Pustular Psoriasis; Erythrodermic Psoriasis | completed | "NCT06323356 (A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-17 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06323356)) |
| October 17, 2025 | [Epioxa Hd/Epioxa Kit (riboflavin 5'-phosphate sodium) FDA approval](https://sec-api.dev/pdufa/riboflavin-5) | GKOS |  | completed, approved | "NDA219910 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20251017, review_priority STANDARD; sponsor_name GLAUKOS; product EPIOXA HD/EPIOXA KIT (RIBOFLAVIN 5'-PHOSPHATE SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219910%22)) |
| October 17, 2025 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA213051 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20251017, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213051%22)) |
| October 17, 2025 | [Tezspire (tezepelumab-ekko) label expansion decision](https://sec-api.dev/pdufa/tezepelumab-ekko) | AZN |  | completed, approved | "BLA761224 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20251017, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product TEZSPIRE (TEZEPELUMAB-EKKO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761224%22)) |
| October 18, 2025 | [LY3541860 primary completion](https://sec-api.dev/pdufa/ly3541860) | LLY | Multiple Sclerosis | withdrawn | "NCT06220669 (A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-18 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-11-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06220669)) |
| October 19, 2025 | [AMGEN INC PDUFA date](https://sec-api.dev/companies/amgn/catalysts) | AMGN | chronic rhinosinusitis with nasal polyps | scheduled | "•FDA review of the WAYPOINT Phase 3 data in patients with chronic rhinosinusitis with nasal polyps is ongoing with a PDUFA date of October 19, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/amgn-20250630earningsrelea.htm)) |
| October 20, 2025 | [Alector, Inc. earnings report](https://sec-api.dev/companies/alec/catalysts) | ALEC |  | completed | "Alector plans to issue guidance for 2026 when it reports fourth quarter and full year 2025 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1653087/000119312525245102/alec-ex99_1.htm)) |
| October 20, 2025 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "Inc. announces preliminary THIRD quarter 2025 results and RAISES 2025 NET REVENUE GUIDANCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390025100156/ea026176001ex99-1_cormedix.htm)) |
| October 20, 2025 | [Opdivo® (nivolumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/nivolumab) | REPL | advanced melanoma in patients | completed | "WOBURN, Mass., October 20, 2025 - Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465925100605/tm2529069d1_ex99-1.htm)) |
| October 20, 2025 | [Qulipta (atogepant) primary completion](https://sec-api.dev/pdufa/atogepant) | ABBV | Episodic Migraine; Chronic Migraine | completed | "NCT04686136 (A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-20 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04686136)) |
| October 20, 2025 | [Setrusumab primary completion](https://sec-api.dev/pdufa/setrusumab) | RARE | Osteogenesis Imperfecta | completed | "NCT05125809 (Setrusumab vs Placebo for Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-10-20 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05125809)) |
| October 20, 2025 | [Mrna-1273.214 primary completion](https://sec-api.dev/pdufa/mrna-1273-214) | MRNA | SARS-CoV-2 | completed | "NCT05436834 (A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-20 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05436834)) |
| October 20, 2025 | [Beyfortus (nirsevimab-alip) label expansion decision](https://sec-api.dev/pdufa/nirsevimab-alip) | AZN |  | completed, approved | "BLA761328 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20251020, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product BEYFORTUS (NIRSEVIMAB-ALIP)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761328%22)) |
| October 21, 2025 | [Bivv020 (sar445088) primary completion](https://sec-api.dev/pdufa/bivv020-sar445088) | SNY | Transplant Rejection | completed | "NCT05156710 (BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-10-21 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05156710)) |
| October 21, 2025 | [Altsonflex1-2-3 dose a primary completion](https://sec-api.dev/pdufa/altsonflex1-2-3) | GSK | Diarrhoea | completed | "NCT06663436 (A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-21 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06663436)) |
| October 22, 2025 | [Medpace Holdings, Inc. earnings report](https://sec-api.dev/companies/medp/catalysts) | MEDP |  | completed | "Medpace Holdings, Inc. Reports Third Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668397/000166839725000108/medp-20251022exx991.htm)) |
| October 22, 2025 | [TNX-2900 trial start](https://sec-api.dev/pdufa/tnx-2900) | TNXP |  | completed | "On October 22, 2025, the Company announced that the first patient was dosed in the investigator-initiated FOCUS study at MGH in adult patients with AVP-D. The FOCUS study is a randomized, double-blind, placebo-controlled crossover pilot study that will evaluate the Company's single-dose investigational intranasal potentiated oxytocin product candidates at two different doses, 6 IU (TNX-2900) and 24 IU (TNX-1900), on markers of anxiety, depression, and socioemotional functioning in patients with AVP-D. An exploratory analysis will assess the effects of two weeks of the investigational product replacement on mental health outcomes." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1430306/000199937125015796/tnxp_8k-102225.htm)) |
| October 22, 2025 | [VS-7375 trial start](https://sec-api.dev/pdufa/vs-7375) | VSTM |  | completed | "GenFleet also shared that the first patient has been dosed in a Phase 1b/2 study of GFH375 combined with cetuximab or chemotherapy for advanced solid tumors on October 22, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm)) |
| October 22, 2025 | [BriaCell Therapeutics Corp. topline data readout](https://sec-api.dev/companies/bctx/catalysts) | BCTX |  | completed, positive | "Center and Winship Cancer Institute of Emory University, and indicated that top-line data could be available as early as the first half of 2026, subject to event accrual.globenewswire.com On October 22, 2025, we disclosed that the independent Data Safety Monitoring Board (DSMB) had issued a fourth consecutive positive recommendation following review of safety data from the Phase 3 trial, identifying no safety concerns and recommending that the study continue without modification; the trial is being conducted under U.S. FDA Fast Track designation." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1610820/000149315225027240/form10-q.htm)) |
| October 22, 2025 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000119312525246775/vktx-ex99_1.htm)) |
| October 22, 2025 | [Hypericin primary completion](https://sec-api.dev/pdufa/hypericin) | SNGX | Psoriasis; Plaque Psoriasis; Psoriasis Vulgaris | completed | "NCT05442190 (Topical SGX302 for Mild-to-Moderate Psoriasis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-22 (ACTUAL); Lead Sponsor Soligenix." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05442190)) |
| October 23, 2025 | [Ozekibart topline data readout](https://sec-api.dev/pdufa/ozekibart) | INBX | advanced or metastatic, unresectable chondrosarcoma and | completed, positive | "On October 23, 2025, Inhibrx announced positive topline results from its registrational trial of ozekibart (INBRX-109) in chondrosarcoma and provided an update on its colorectal cancer and Ewing sarcoma expansion cohorts." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000094/exhibit99109302025.htm)) |
| October 23, 2025 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "Harmony will report full third quarter 2025 financial results on Tuesday, November 4th, 2025, before the open of the U.S. financial markets." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/hrmy-20251023xex99d1.htm)) |
| October 23, 2025 | [Annamycin trial start](https://sec-api.dev/pdufa/annamycin) | MBRX |  | completed | "On October 23, 2025, Moleculin Biotech, Inc. (the "Company"), issued a press release which announced that the Company has entered into an agreement with Atlantic Health System, Inc. to commence an investigator-initiated Phase 1B/2 single-arm study evaluating Annamycin for third-line ("3L") treatment of advanced pancreatic cancer." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1659617/000143774925031574/mbrx20251020_8k.htm)) |
| October 23, 2025 | [GSK plc PDUFA date](https://sec-api.dev/companies/gsk/catalysts) | GSK |  | scheduled | "Constructive discussion ongoing with FDA with new PDUFA date set for 23 October 2025" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425008641/a0713t-gskplc2ndquarterre.htm)) |
| October 23, 2025 | [Blenrep (belantamab mafodotin-blmf) FDA approval](https://sec-api.dev/pdufa/belantamab-mafodotin-blmf) | GSK |  | completed, approved | "BLA761440 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20251023, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product BLENREP (BELANTAMAB MAFODOTIN-BLMF)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761440%22)) |
| October 23, 2025 | [Blenrep (belantamab mafodotin-blmf) complete response letter (CRL)](https://sec-api.dev/pdufa/belantamab-mafodotin-blmf) | GSK |  | completed, complete response letter | "We have completed the review of BLA 761440/Original 2, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761440_20251023.pdf%22)) |
| October 23, 2025 | [Bisphosphonate primary completion](https://sec-api.dev/pdufa/bisphosphonate) | RARE | Osteogenesis Imperfecta | completed | "NCT05768854 (Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-23 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05768854)) |
| October 23, 2025 | [Sar444656 (kt-474) primary completion](https://sec-api.dev/pdufa/sar444656-kt-474) | SNY | Atopic Dermatitis | withdrawn | "NCT06058156 (Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-23 (ACTUAL); Lead Sponsor Sanofi; Results First Posted 2026-11-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06058156)) |
| October 23, 2025 | [PF-07976016 primary completion](https://sec-api.dev/pdufa/pf-07976016) | PFE | Obesity | completed | "NCT06717425 (A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-23 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06717425)) |
| October 24, 2025 | [Revuforj® (revumenib) FDA approval](https://sec-api.dev/pdufa/revumenib) | SNDX | relapsed or refractory | completed, approved | "On October 24, 2025, Syndax Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved Revuforj® (revumenib) for the treatment of relapsed or refractory ("R/R") acute myeloid leukemia ("AML") with a susceptible nucleophosmin 1 ("NPM1") mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1395937/000119312525250052/sndx-20251024.htm)) |
| October 24, 2025 | [Revuforj® (revumenib) label expansion decision](https://sec-api.dev/pdufa/revumenib) | SNDX |  | completed, approved | "NDA218944 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20251024, review_priority PRIORITY; sponsor_name SYNDAX; product REVUFORJ (REVUMENIB CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218944%22)) |
| October 24, 2025 | [Winrevair (sotatercept-csrk) label expansion decision](https://sec-api.dev/pdufa/sotatercept-csrk) | MRK |  | completed, approved | "BLA761363 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20251024, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WINREVAIR (SOTATERCEPT-CSRK)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761363%22)) |
| October 25, 2025 | [Revuforj® (revumenib) PDUFA date](https://sec-api.dev/pdufa/revumenib) | SNDX |  | completed, approved | "PDUFA target action date of October 25, 2025 IC, intensive chemotherapy" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_2.htm)) |
| October 25, 2025 | [WINREVAIR (sotatercept) PDUFA date](https://sec-api.dev/pdufa/sotatercept) | MRK |  | scheduled | "FDA Granted Priority Review for WINREVAIR to Update Label Based on Results From ZENITH Trial; FDA Set PDUFA Date of Oct. 25, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465925071380/tm2521736d1_ex99-1.htm)) |
| October 25, 2025 | [NIKTIMVO (axatilimab) PDUFA date](https://sec-api.dev/pdufa/axatilimab) | SNDX |  | scheduled | "- sNDA in R/R mNPM1 AML granted Priority Review; PDUFA action date of October 25, 2025 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_1.htm)) |
| October 27, 2025 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847725000104/earningsrelease-27oct25ex9.htm)) |
| October 27, 2025 | [NRC HEALTH earnings report](https://sec-api.dev/companies/nrc/catalysts) | NRC |  | completed | "NRC HEALTH ANNOUNCES THIRD QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/70487/000143774925031819/ex_875834.htm)) |
| October 27, 2025 | [Opdivo Qvantig (hyaluronidase-nvhy; nivolumab) label expansion decision](https://sec-api.dev/pdufa/hyaluronidase-nvhy-nivolumab) | BMY |  | completed, approved | "BLA761381 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20251027, review_priority STANDARD; sponsor_name BRISTOL-MYERS SQUIBB; product OPDIVO QVANTIG (HYALURONIDASE-NVHY; NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761381%22)) |
| October 27, 2025 | [VYGLXIA (troriluzole) primary completion](https://sec-api.dev/pdufa/troriluzole) | BHVN | Obsessive-Compulsive Disorder | completed | "NCT04641143 (Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor Biohaven Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04641143)) |
| October 27, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Bladder Cancer | completed | "NCT04700124 (Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04700124)) |
| October 27, 2025 | [Efimosfermin primary completion](https://sec-api.dev/pdufa/efimosfermin) | GSK | Nonalcoholic Steatohepatitis (NASH) | completed | "NCT04880031 (A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04880031)) |
| October 27, 2025 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | completed | "NCT06333808 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-11-05." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06333808)) |
| October 28, 2025 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000110465925102834/tm2529531d1_ex99-1.htm)) |
| October 28, 2025 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000119312525252207/alks-ex99_1.htm)) |
| October 28, 2025 | [REPLIGEN CORP earnings report](https://sec-api.dev/companies/rgen/catalysts) | RGEN |  | completed | "Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/730272/000119312525252385/rgen-ex99_1.htm)) |
| October 28, 2025 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000142/pressreleaseex991q32025.htm)) |
| October 28, 2025 | [IQVIA HOLDINGS INC. earnings report](https://sec-api.dev/companies/iqv/catalysts) | IQV |  | completed | "IQVIA Reports Third-Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478242/000162828025046554/iqv-q3x2025earningspressre.htm)) |
| October 28, 2025 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916925000115/incy-q32025xexx991.htm)) |
| October 28, 2025 | [Oxylanthanum complete response letter (CRL)](https://sec-api.dev/pdufa/oxylanthanum) | UNCY | kidney disease | completed, complete response letter | "On October 28, 2025, we announced an update from our meeting with the U.S. Food and Drug Administration (FDA) and timing of the resubmission of our New Drug Application (NDA) for Oxylanthanum carbonate (OLC) following receipt of a CRL on June 30, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/ea0300450-10q_unicycive.htm)) |
| October 28, 2025 | [DBV Technologies S.A. earnings report](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed | "DBV Technologies Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312525253968/d53703dex991.htm)) |
| October 28, 2025 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (October 28, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/exhibit991q32025.htm)) |
| October 28, 2025 | [Arcus Biosciences, Inc. earnings report](https://sec-api.dev/companies/rcus/catalysts) | RCUS |  | completed | "Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1724521/000172452125000114/a2025q38kexhibit991.htm)) |
| October 28, 2025 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "Neurocrine Biosciences Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447525000180/q3-2025xearningsrelease.htm)) |
| October 28, 2025 | [Nucala (mepolizumab) primary completion](https://sec-api.dev/pdufa/mepolizumab) | GSK | Hypereosinophilic Syndrome | completed | "NCT04965636 (Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-05-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04965636)) |
| October 28, 2025 | [TAK-771 primary completion](https://sec-api.dev/pdufa/tak-771) | TAK |  | completed | "NCT05084053 (A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2025-03-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05084053)) |
| October 28, 2025 | [Lenrispodun primary completion](https://sec-api.dev/pdufa/lenrispodun) | JNJ | Parkinson Disease | completed | "NCT05766813 (Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05766813)) |
| October 28, 2025 | [AZD4604 primary completion](https://sec-api.dev/pdufa/azd4604) | AZN | Asthma | completed | "NCT06020014 (Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06020014)) |
| October 29, 2025 | [Fulcrum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fulc/catalysts) | FULC |  | completed | "Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680581/000119312525254619/fulc-ex99_1.htm)) |
| October 29, 2025 | [KYV-101 interim data readout](https://sec-api.dev/pdufa/kyv-101) | KYTX |  | completed, positive | "EMERYVILLE, Calif., October 29, 2025 - Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive interim data from the Phase 2 portion of the registrational KYSA-6 clinical trial of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1994702/000119312525254571/d80007dex991.htm)) |
| October 29, 2025 | [Savara Inc FDA approval](https://sec-api.dev/companies/svra/catalysts) | SVRA |  | completed, approved | "LANGHORNE, PA - October 29, 2025 - Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced a $75 million royalty funding agreement with funds managed by RTW Investments, LP (RTW), subject to FDA approval of MOLBREEVI." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1160308/000119312525256290/d55049dex991.htm)) |
| October 29, 2025 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/vnda8-k10292025exhibit991.htm)) |
| October 29, 2025 | [OPKO HEALTH, INC. earnings report](https://sec-api.dev/companies/opk/catalysts) | OPK |  | completed | "OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/944809/000119312525256325/opk-ex99_1.htm)) |
| October 29, 2025 | [Encaleret topline data readout](https://sec-api.dev/pdufa/encaleret) | BBIO |  | completed, positive | "PALO ALTO, CA - October 29, 2025 - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced positive topline results from" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000114036125039705/ef20057894_ex99-1.htm)) |
| October 29, 2025 | [AMARIN CORP PLCUK earnings report](https://sec-api.dev/companies/amrn/catalysts) | AMRN |  | completed | "Amarin Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/897448/000119312525254620/amrn-ex99_1.htm)) |
| October 29, 2025 | [Tectonic Therapeutic, Inc. topline data readout](https://sec-api.dev/companies/tecx/catalysts) | TECX | Group 2 PH-HFrEF | completed, positive | "TECX) ("Tectonic"), today announced positive topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45, a long-acting, Fc-relaxin fusion protein, in patients with Group 2 PH-HFrEF." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1681087/000119312525256958/d30823dex992.htm)) |
| October 29, 2025 | [Bausch Health Companies Inc. earnings report](https://sec-api.dev/companies/bhc/catalysts) | BHC |  | completed | "BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/885590/000088559025000048/ex991-q3x2025.htm)) |
| October 29, 2025 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000198/ebs2025-09x30ex99er.htm)) |
| October 29, 2025 | [IONIS PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/ions/catalysts) | IONS |  | completed | "Ionis reports third quarter 2025 financial results and highlights progress on key programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036125039650/ef20057869_ex99-1.htm)) |
| October 29, 2025 | [IMMUTEP Ltd trial start](https://sec-api.dev/companies/immp/catalysts) | IMMP |  | completed | "As previously announced, the investigator-initiated EFTISARC-NEO Phase II trial has met its primary endpoint." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506184/000119312525257286/d25202dex991.htm)) |
| October 29, 2025 | [Rafael Holdings, Inc. earnings report](https://sec-api.dev/companies/rfl/catalysts) | RFL |  | completed | "NEWSWIRE) - Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-W), today reported its financial results for the fourth quarter and full fiscal year 2025 ended July 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1713863/000121390025103509/ea026292601ex99-1_rafael.htm)) |
| October 29, 2025 | [Libtayo (cemiplimab-rwlc) label expansion decision](https://sec-api.dev/pdufa/cemiplimab-rwlc) | REGN |  | completed, approved | "BLA761097 SUPPL-32 (Efficacy): submission_status AP, submission_status_date 20251029, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22)) |
| October 29, 2025 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000108255425000036/uthrq32025-ex991.htm)) |
| October 29, 2025 | [BridgeBio Pharma, Inc. earnings report](https://sec-api.dev/companies/bbio/catalysts) | BBIO |  | completed | "PALO ALTO, CA - October 29, 2025 - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced its financial results for the third quarter ended September 30, 2025, and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388125000010/bbio-20250930xex991.htm)) |
| October 30, 2025 | [BIO-TECHNE Corp earnings report](https://sec-api.dev/companies/tech/catalysts) | TECH |  | completed | "Minneapolis/November 5, 2025/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/842023/000110465925106631/tech-20251030xex99d1.htm)) |
| October 30, 2025 | [Apazunersen trial start](https://sec-api.dev/pdufa/apazunersen) | RARE |  | completed | "On October 30, 2025, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing that the first patient has been dosed in the Aurora study (NCT07157254) evaluating the efficacy and safety of GTX-102 (apazunersen), an investigational antisense oligonucleotide ("ASO") for Angelman syndrome ("AS")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312525257538/rare-20251030.htm)) |
| October 30, 2025 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000162828025047342/alny2025q3earningsrelease.htm)) |
| October 30, 2025 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports Third Quarter Financial Results for 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427225000147/a2025q3ex991.htm)) |
| October 30, 2025 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000059/amrx-q32025ex991.htm)) |
| October 30, 2025 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS THIRD-QUARTER 2025 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000143774925032422/ex_870706.htm)) |
| October 30, 2025 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000114/agio-103125xfyxex991earnin.htm)) |
| October 30, 2025 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000143740225000016/ardx-20250930xexhibit991.htm)) |
| October 30, 2025 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/tm2529620d1_ex99-1.htm)) |
| October 30, 2025 | [Syndrome interim data readout](https://sec-api.dev/pdufa/syndrome) | NGNE |  | completed, positive | "The Embolden trial builds on positive interim data from the Phase 1/2 trial of NGN-401, which demonstrated multidomain, durable gains with continued developmental milestone acquisitions as of the most recently disclosed safety and efficacy data, with a cutoff date of October 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000044/ngne_prxemboldendosingcomp.htm)) |
| October 30, 2025 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000044/exhibit991earningspressrel.htm)) |
| October 30, 2025 | [Supernus, Inc. earnings report](https://sec-api.dev/companies/supn/catalysts) | SUPN |  | completed | "Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312525257381/d58033dex991.htm)) |
| October 30, 2025 | [Inmune Bio, Inc. earnings report](https://sec-api.dev/companies/inmb/catalysts) | INMB |  | completed | "Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711754/000121390025104154/ea026319601ex99-1_inmune.htm)) |
| October 30, 2025 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "Travere Therapeutics Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000055/a2025q3_8-kxex991.htm)) |
| October 30, 2025 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947825000251/q325lillysalesandearningsp.htm)) |
| October 30, 2025 | [BICYCLE THERAPEUTICS PLC earnings report](https://sec-api.dev/companies/bcyc/catalysts) | BCYC |  | completed | "CAMBRIDGE, England & BOSTON, October 30, 2025 - Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761612/000110465925104004/tm2529754d1_ex99-1.htm)) |
| October 30, 2025 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312525257382/d68071dex991.htm)) |
| October 30, 2025 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen reports strong third quarter 2025 results and updates full year 2025 guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000047/exhibit991-q32025pressrele.htm)) |
| October 30, 2025 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_ex99-1.htm)) |
| October 30, 2025 | [Otezla (apremilast) primary completion](https://sec-api.dev/pdufa/apremilast) | AMGN | Psoriasis | completed | "NCT04175613 (A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04175613)) |
| October 30, 2025 | [AQVESME™ (mitapivat) primary completion](https://sec-api.dev/pdufa/mitapivat) | AGIO | Sickle Cell Disease | completed | "NCT05031780 (A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05031780)) |
| October 30, 2025 | [TAK-771 primary completion](https://sec-api.dev/pdufa/tak-771) | TAK | Primary Immunodeficiency Diseases (PID) | completed | "NCT05513586 (A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05513586)) |
| October 31, 2025 | [MBX Biosciences, Inc. earnings report](https://sec-api.dev/companies/mbx/catalysts) | MBX |  | completed | "MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776111/000119312525268146/mbx-ex99_1.htm)) |
| October 31, 2025 | [Juvmo (tavapadon) NDA/BLA submission](https://sec-api.dev/pdufa/tavapadon) | ABBV | Parkinson's disease | completed | "•AbbVie announced that it submitted a New Drug Application (NDA) to the FDA for tavapadon, a novel selective dopamine D1/D5 receptor partial agonist for the treatment of Parkinson's disease (PD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/abbv-20250930xexhibit991.htm)) |
| October 31, 2025 | [Avto5 complete response letter (CRL)](https://sec-api.dev/pdufa/avto5) | ALVO |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761462_20251031.pdf%22)) |
| October 31, 2025 | [RINVOQ® (upadacitinib) label expansion decision](https://sec-api.dev/pdufa/upadacitinib) | ABBV | with moderately to severely active ulcerative colitis | completed, approved | "•AbbVie announced the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) that updates the indication statement for Rinvoq (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/abbv-20250930xexhibit991.htm)) |
| October 31, 2025 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports Third-Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/abbv-20250930xexhibit991.htm)) |
| October 31, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Non-Small-Cell Lung | completed | "NCT04165083 (KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-31 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04165083)) |
| October 31, 2025 | [ONUREG (azacitidine) primary completion](https://sec-api.dev/pdufa/azacitidine) | BMY | Leukemia, Myeloid, Acute | completed | "NCT05413018 (An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-10-31 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05413018)) |
| October 31, 2025 | [Fasedienol nasal spray primary completion](https://sec-api.dev/pdufa/fasedienol-nasal-spray) | VTGN | Social Anxiety Disorder | completed | "NCT06358651 (Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-31 (ACTUAL); Lead Sponsor VistaGen Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06358651)) |

Other months: https://sec-api.dev/fda-calendar/2025-09 , https://sec-api.dev/fda-calendar/2025-11. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates October 2025: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2025-10

```bibtex
@misc{secapidev_fda_calendar_2025_10_20261116,
  title        = {PDUFA dates October 2025: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2025-10}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2025_10_20261116","title":"PDUFA dates October 2025: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2025-10","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
